Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 90

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 90
---
 tolerated in preclinical studies, with no significant adverse 
 effects reported [3]. However, these are pre-clinical indications that need to confirmed       
 in appropriate clinical studies.                                                               |

| - | WHO Priority Pathogens: The                                                                        
 World Health Organization (WHO) lists MRSA, VRE, and Neisseria gonorrhoeae among its high-priority 
 pathogens due to increasing antimicrobial resistance [5]. Nano-Mupirocin demonstrated activity     
 against these bacteria which supports its potential relevance in global health initiatives.        |

A team of researchers from the National Institute
of Health in collaboration with Prof. Barenholtz’s team have demonstrated proof of concept in a number of preclinical studies performed
on resistant bacteria which causes severe life-threating infections including necrotizing fasciitis, endocarditis, and gonorrhea. A few
in vitro and in vivo studies testing novel LNP mupirocin were supported and conducted in collaboration with the National
Institute of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID). The results were published in the Antimicrobial
Agents and Chemotherapy journal [6] as well as in the Journal of Controlled Release [7].

While the abovementioned attributes have been observed in preclinical
models, there can be no assurance that they will be replicated in clinical studies or translate into meaningful patient outcomes.

References

| 1. | Williams JD. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrobial Agents and Chemotherapy. 1985;27(4):495–498. DOI: 10.1128/aac.27.4.495 |

| 2. | DrugBank Online: Mupirocin (DB00410). DrugBank. https://go.drugbank.com/drugs/DB00410 |

| 3. | Kulkarni NS, et al. Therapeutic potential of injectable nano-mupirocin liposomes against MRSA and VRE infections. Pharmaceutics. 2021;13(11):1789. PMC8706398 |

| 4. | He W, et al. Enhanced uptake of antibiotic-loaded nanoparticles by macrophages improves intracellular killing of pathogens. Journal of Controlled Release. 2021;336:149–162. |

| 5. | WHO. WHO Bacterial Priority                                                 
 Pathogens List, 2024. https://www.